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Abstract
Surgery remains a main part of the treatment of most solid tumors.
Paradoxically, rapid disease progression may be a consequence of surgery
in patients presenting with a dysregulated inflammatory response, and
increased angiogenesis consequent to a suppressed antitumoral immune
response. Physicians taking care of cancer patients should be aware of the
important findings that indicate that analgesic techniques could play a role
in these phenomena.
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Introduction
The natural history of cancer is a complex and rapidly evolving 
field. For example, in breast cancer, the growth of the primary tumor 
and the dissemination of neoplastic cells are linked, at least in part, 
to inflammation leading to immune dysfunction and an/or increased 
angiogenesis1,2. For breast cancer, as well as for most solid tumors, 
surgery remains a main part of the treatment. However, paradoxi-
cally, the surgical period, and the associated inflammatory reaction, 
is itself a high risk factor for the development of metastases and 
this phenomenon may be explained by the rapid release of inducers 
of angiogenesis concomitant to a profound immunosuppression1,2. 
One example, sometimes observed, is the rapid postoperative devel-
opment of additional tumors and metastasis when a primary tumor 
is surgically removed2.
Other factors can accentuate this phenomenon, including the meta-
bolic and hormonal changes that occur and are determined by the 
inflammatory/catecholaminergic “stress reaction” to surgery3. To 
counteract these effects, perioperative physicians, including an-
esthesiologists, surgeons and oncologists, must help the patient to 
maintain homeostasis against the consequences of both cancer and 
tissular attrition. Anesthetic and analgesic techniques are one part of 
this strategy, but their effects, however important, are different and 
not well understood. Indeed, these drugs may influence immunity 
and tumor development, either directly by interfering with cellular 
mechanisms (e.g. cell apoptosis) or indirectly by interactions with 
the endocrine and sympathetic systems.
In this paper, we discuss the consequences of perioperative inflamma-
tion in cancer surgery on immunity and angiogenesis. Secondly, we de-
scribe why analgesic techniques may play a role in these phenomena.
Perioperative inflammation-related immunosuppression 
and neoangiogenesis are seen in cancer patients at 
risk of relapse
The early existence of dormant metastasis is matter of debate2. One 
argument is the kinetics observed in cancer recurrence after breast 
cancer surgery. Indeed, when analyzing the timing of the relapse of 
patients under endocrine therapy, recurrences occur gradually over 
the first 10 to 15 years. In contrast, in women not treated with en-
docrine therapy (i.e. with estrogen-receptor-negative tumors), the 
majority of cancer relapses occur in the first two years4. This sug-
gests that these tumor cells have been maintained in a “dormant” 
state in the first group of women, whereas they may be present early 
in both groups5.
The risk for these patients in undergoing surgery is that rapid 
growth of these cells could be induced through perioperative 
inflammation. Indeed, following a surgical trauma, a great, but 
short-lasting, inflammation is correlated with a potent immune 
response that precedes a longer duration of immunosuppression1. 
The role of this immunosuppression is probably to minimize the 
intensity of the proinflammatory response, and reduce the risks 
of autoimmune disorders and/or necrosis of tissue6,7. Locally and 
throughout the body, the release of cytokines underlies the initia-
tion, maintenance and regulation of the inflammatory response. 
After tissue injury, monocytes and macrophages rapidly release 
interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF-α). IL-1 
stimulates and maintains the secretion of other cytokines such as 
interleukin 6 (IL-6) that are major mediators of the systemic ef-
fects of the stress response. The production of adrenocorticotropic 
hormone (ACTH) and cortisol are stimulated and are regulated by 
a negative feedback system8.
The tissue damage caused by surgery is also likely to generate 
pain. This causes the secretion of endogenous opioids that provide 
analgesia of short duration by their peripheral and central effects9. 
Peripherally, the presence of opioid receptors on immune cells 
allows β-endorphins to have a direct effect on the proliferation, 
migration and cytotoxicity of these cells9. Some neurotransmit-
ters, including substance P, can interact with the pain pathways. 
At the central level, active pain regulatory mechanisms act via 
the periaqueductal gray matter of the midbrain and through the 
β-endorphin and catecholaminergic pathways. Norepinephrine in-
hibits natural killer (NK) cell activity via the β-2 receptor. The 
cholinergic system and the vagus nerve play a role that is often 
opposite to that of the sympathetic system10.
In turn, the brain monitors and controls these loops of inflamma-
tion. The hypothalamic-pituitary, cortex and cerebellum are in-
volved in the control of lymphoid organs, especially the spleen and 
many adrenergic receptors are present on B and T lymphocytes, 
macrophages, neutrophils and NK cells. Finally, the endocrine 
system interacts with the brain, immune cells and most organs6,7. 
Glucocorticoids, for example, have anti-inflammatory properties 
but are essential for normal immune response. Prostaglandins and 
prostacyclin, particularly PGE2, are produced, among others, by 
dendritic cells and macrophages. They have a major role in the 
regulation of immunity in general and NK activity in particular. In 
addition, PGE2 plays a major role in the stimulation of epithelial 
cell proliferation, inhibition of apoptosis, production of mutagens 
and stimulation of angiogenesis11. This may explain the high in-
cidence of overexpression of COX-2 in breast cancer, as in other 
cancers, and higher aggressiveness of these tumors11.
Neo-angiogenesis is probably a major step in the induction of 
growth of a dormant metastasis. Indeed, it appears that solid tumors 
cannot grow larger than 2–3 mm in diameter unless they induce 
their own blood supply12. The expression of the angiogenic phe-
notype, physiologically to promote wound healing, is a complex 
process that depends on a number of cellular and molecular events, 
including degradation of the surrounding basement membrane, 
migration of endothelial cells, cell proliferation, the formation of 
tube-like structures and the maturation of these endothelial-lined 
tubes into new blood vessels13.
As a consequence, most of the modifications in the immune system 
and the angiogenesis phenotype are linked to the degree of tissue 
injury and its consequent inflammation. The logical strategy is then 
to promote minimally invasive surgery that is designed to limit these 
impacts, to maintain homeostasis14 and reduce the stress response8. 
These arguments have led some authors to consider that minimally 
invasive procedures might be favorable in terms of immunity when 
compared with invasive procedures due to the need to manage other 
changes driven by the “secondary aggressions”, i.e., hypothermia, 
hemorrhage, and psychological factors such as anxiety1.
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Effect of analgesics on inflammation, anticancer 
immunity and angiogenesis
A possible way to influence the perioperative inflammatory reac-
tion and their consequences for immune cells and angiogenesis is 
by modifying analgesic techniques. This could have an important 
impact on patient outcome following surgery.
Macrophages, T lymphocytes, NK T and other cells and many 
cytokines are involved in the defense mechanisms of nonspecific 
immunity. Of these, the role of NK cells in defense against infec-
tion and the development of tumor cells1,15–17 has been largely dem-
onstrated. The study of animal models has helped us to understand 
their role in the mechanisms behind perioperative anti-metastatic 
protection, but also their vulnerability16–18. In humans, a significant 
correlation between NK activity and patient prognosis is related 
to the development of metastases19. The strong depression of the 
cytotoxicity of the NK cells in the perioperative period may signifi-
cantly alter the defense mechanisms of patients1.
Analgesic techniques that reduce the inflammatory response may be 
favorable in terms of immunity8. Recent data suggest that the analge-
sic techniques (intravenous opioids, non-steroidal anti-inflammatory 
drugs (NSAIDs) and locoregional analgesia) could have an impact 
on the long-term prognosis after cancer surgery20,21, including for 
breast cancer22,23. Opioids are the drugs most studied in the context 
of the perioperative immune response. In the absence of pain, mor-
phine induces a decrease in NK activity25. It is not clear whether it 
is the opioids, but possibly also the withdrawal of opioid therapy, 
that is responsible for opioid-induced immunosuppression24. Never-
theless, pain itself induces a significant immune response. Because 
this response leads to a significant degree of immunosuppression, 
postoperative analgesia is, by itself, immunoprotective1. Morphine 
therefore allows the maintenance of NK activity and protection 
against metastasis in animal pain models25. In humans, similar 
arguments can be used to offer the lowest effective dose of opioid24. 
Data on synthetic opioids have revealed a similar phenomenon with 
fentanyl and sufentanil, probably mediated via the µ-opioid recep-
tor. Nevertheless, differences linked to selective µ1-activation by 
synthetic opioids, in contrast to µ3-activation by morphine, could 
explain the more favorable profile of morphine and may merit fur-
ther investigation25. Opioids could also affect angiogenesis and the 
growth of tumors. In the perioperative period and after tissue injury, 
important angiogenic signals, including epithelial growth factors 
(VEGF), act via receptor tyrosine kinases and G-protein-coupled 
receptor (GPCR). This may have a major importance as morphine 
can transactivate these GPCR, increasing neo-angiogenesis13.
Prostaglandins are another major perioperative influence on immu-
nity and angiogenesis and the promotion of tumor growth26. The 
data concerning the maintenance of NK activity by NSAIDs are 
encouraging, in some, but only a few human clinical studies. In a 
retrospective study, we showed that receiving ketorolac, a NSAID, 
just before surgery, was an independent factor associated with 
longer recurrence-free survival after breast cancer surgery22. These 
results may be explained by the fact that prostaglandin E2 (PGE2), 
released by monocytes and dendritic cells in order to regulate the 
inflammatory cascade, profoundly depresses cellular antitumoral 
immunity, i.e. NK activity27. This suppression of NK activity, and 
possibly an initial flare-up of angiogenesis, dissipates quickly af-
ter the removal of the prostaglandins. There may then be a short 
therapeutic window when NSAIDs may have a potent impact on the 
oncological outcome22.
It seems clear that regional anesthesia, particularly central blocks, 
are associated with anti-inflammatory effects, and allow the pro-
tection of anticancer immunity, including NK activity, after major 
surgery28, but this effect has not been demonstrated after minor 
surgery29. It is possible that this effect is responsible for a lower 
incidence of recurrence after surgery for breast, colon or prostate 
cancers, however this is an unresolved debate due to poor method-
ology and lack of perioperative immune monitoring20,21,23,30–33.
Anesthesiologists are using many other drugs that are not nec-
essarily associated with analgesic effects. Data are sparse and 
mostly inconclusive concerning barbiturates, halogenated gases, 
propofol and etomidate. It seems likely that ketamine, a widely 
used co-analgesic, has a dose-dependent effect, being protective 
at low doses during a painful stimulus and potentially harmful 
at high doses in the absence of surgery24. One interesting topic is 
the potential protective role of alpha-2-agonists, such as clonidine, 
typically used as co-analgesic during surgery on perioperative NK 
activity24.
Is it time to change our pain management practices?
A goal of optimal control of pain may appear to be obvious, but 
it still remains a major concern for perioperative physicians. The 
quality of analgesia is facilitated by combinations of molecules 
(NSAIDs and anti-hyperalgesics such as ketamine) and techniques 
(intravenous, locoregional with local anesthetics). At this time, it is 
not clear whether these techniques may improve oncological out-
come alone, indirectly by the avoidance of opioids, or both. Nev-
ertheless, they improve pain management, postoperative rehabilita-
tion and the prognosis for patients. These reasons remain the main 
argument to recommend such analgesic approaches before defini-
tive conclusions on their influence on the oncological outcome8,14.
Moreover, it appears that high doses of opioids are carriers of long-
term side effects that are probably underestimated (including opi-
oid-induced hyperalgesia). The study of the role opioids play in the 
increase in angiogenesis and postoperative immunosuppression is 
of particular importance in oncological surgery, knowing that NK 
activity could be a prognostic criterion13,19. Taking into account that 
they improve pain management, it is appropriate to propose opioid-
sparing strategies, such as locoregional techniques and sympathetic 
modulation using intravenous α-2 agonists24.
Conclusions
Understanding cancer development mechanisms is a major goal of 
clinical research and may lead to the development of strategies to 
counter the multiple factors involved in cancer pathology. It is very 
important to study all aspects of the problem, permitting the devel-
opment of strategies associated with a higher long term survival 
after cancer surgery. The data available already affirm that the im-
mune system and the angiogenesis phenotype play key roles in an-
ticancer defenses, that the potential influence of surgery-related in-
flammation is large and that the effects of drugs and the techniques 
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of analgesia may be important. Perioperative physicians must be 
aware that an optimal analgesic strategy may have along-term 
impact on patient outcome.
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